To determine whether nifedipine, a calcium antagonist, protects ischemic myocardium, conscious dogs were subjected to coronary occlusion and given nifedipine by intravenous infusion beginning 30 minutes after the onset of ischemia and lasting for 24 hours while systemic arterial pressure, left atrial pressure, and cardiac output were monitored. Local myocardial perfusion at selected intervals after coronary occlusion was assessed with radioactive microspheres injected into the left atrium. In regions of myocardium exhibiting moderately depressed flow 29 minutes after occlusion in control dogs (n = 8), flow was significantly greater 3 and 23.5 hours later, reflecting increases in collateral perfusion. Corresponding zones of myocardium in treated dogs (n = 9) exhibited significantly greater increases in flow at each interval after occlusion (P < 0.05). Furthermore, myocardial creatine kinase depletion (which correlated well with morphometric estimates of necrosis) in myocardium matched for ischemia prior to treatment was 1.5 to 3 times less in treated than in control dogs {P < 0.05). Thus, nifedipine produced sustained increases in collateral flow and reduced myocardial ischemic injury. NIFEDIPINE, a 1,4-dihydropyridine derivative that inhibits the contractile activity of smooth and cardiac muscle, 1 " 3 has several pharmacological properties in common with agents used in the treatment of myocardial ischemia. Like nitroglycerin, it is a potent coronary dilator and an effective antianginal agent; 4 ' 5 like nitroprusside, 6 it reduces peripheral arterial impedance, unloads the left ventricle, and may increase cardiac output; 7 ' 8 and like propranolol, it decreases cardiac contractility and myocardial oxygen uptake. 9 ' 10 Although nifedipine is not an adrenergic receptor blocking agent 1 and does not inhibit the release of sympathetic neurotransmitter, 11 it antagonizes effects of catecholamines indirectly. 12 These pharmacological properties suggest that nifedipine ultimately may prove useful for the treatment of severe myocardial ischemia in man. In the present study, we have examined the effects of nifedipine on the myocardium of conscious dogs subjected to acute coronary occlusion. Our results indicate that the drug produces sustained increases in myocardial perfusion in ischemic zones and reduces ischemic injury. positive pressure ventilation with room air, a left thoracotomy was performed, the pericardium opened, and an occlusive snare placed around the left anterior descending coronary artery (LAD) below the origin of the first major diagonal branch. Silastic catheters (2.13 mm o.d., 1.0 mm i.d.; Dow Corning) were inserted in the jugular vein, central aorta, and left atrium, and an electromagnetic flow transducer (Narco Biosystems, C series, 18-20 mm) was placed around the ascending aorta. The free ends of the transducer cables, snare, and catheters were exteriorized dorsally at the base of the neck and the chest was closed. Each dog was allowed to recover for 11-17 days.
Effects of Nifedipine on Myocardial Perfusion and Ischemic Injury in Dogs
SUMMARY To determine whether nifedipine, a calcium antagonist, protects ischemic myocardium, conscious dogs were subjected to coronary occlusion and given nifedipine by intravenous infusion beginning 30 minutes after the onset of ischemia and lasting for 24 hours while systemic arterial pressure, left atrial pressure, and cardiac output were monitored. Local myocardial perfusion at selected intervals after coronary occlusion was assessed with radioactive microspheres injected into the left atrium. In regions of myocardium exhibiting moderately depressed flow 29 minutes after occlusion in control dogs (n = 8), flow was significantly greater 3 and 23.5 hours later, reflecting increases in collateral perfusion. Corresponding zones of myocardium in treated dogs (n = 9) exhibited significantly greater increases in flow at each interval after occlusion (P < 0.05). Furthermore, myocardial creatine kinase depletion (which correlated well with morphometric estimates of necrosis) in myocardium matched for ischemia prior to treatment was 1.5 to 3 times less in treated than in control dogs {P < 0.05). Thus, nifedipine produced sustained increases in collateral flow and reduced myocardial ischemic injury.
NIFEDIPINE, a 1,4-dihydropyridine derivative that inhibits the contractile activity of smooth and cardiac muscle, 1 " 3 has several pharmacological properties in common with agents used in the treatment of myocardial ischemia. Like nitroglycerin, it is a potent coronary dilator and an effective antianginal agent; 4 ' 5 like nitroprusside, 6 it reduces peripheral arterial impedance, unloads the left ventricle, and may increase cardiac output; 7 ' 8 and like propranolol, it decreases cardiac contractility and myocardial oxygen uptake. 9 ' 10 Although nifedipine is not an adrenergic receptor blocking agent 1 and does not inhibit the release of sympathetic neurotransmitter, 11 it antagonizes effects of catecholamines indirectly. 12 These pharmacological properties suggest that nifedipine ultimately may prove useful for the treatment of severe myocardial ischemia in man. In the present study, we have examined the effects of nifedipine on the myocardium of conscious dogs subjected to acute coronary occlusion. Our results indicate that the drug produces sustained increases in myocardial perfusion in ischemic zones and reduces ischemic injury.
positive pressure ventilation with room air, a left thoracotomy was performed, the pericardium opened, and an occlusive snare placed around the left anterior descending coronary artery (LAD) below the origin of the first major diagonal branch. Silastic catheters (2.13 mm o.d., 1.0 mm i.d.; Dow Corning) were inserted in the jugular vein, central aorta, and left atrium, and an electromagnetic flow transducer (Narco Biosystems, C series, 18-20 mm) was placed around the ascending aorta. The free ends of the transducer cables, snare, and catheters were exteriorized dorsally at the base of the neck and the chest was closed. Each dog was allowed to recover for 11-17 days.
Hemodynamic Measurements
Hemodynamic measurements were made in conscious, loosely restrained dogs while they were lying quietly on the right side. The implanted Silastic catheters were connected to Statham pressure transducers (P23Db) and signals were amplified with Honeywell Accudata 143 amplifiers and recorded with a Honeywell fiberoptic recorder (model 1858). Cardiac output was measured with a Narco Biosystems, model RT-500 digital readout flowmeter. Regional coronary flow was estimated by the labeled microsphere method 13 with carbonized microspheres, 15 ± 3 fim in diameter, labeled witĥ Sr, 141 Ce, or 51 Cr (3M Company). Microspheres were suspended in isotonic saline, treated sonically for 15 minutes in a 3M Company model DA 0950 ultrasonic bath, and vigorously agitated immediately before injection. For each flow measurement, approximately 3 to 4 X 10 6 tracer microspheres (10-25 juCi) in 1.5 ml of warm saline at 38°C were injected with a Harvard Model 975 syringe pump through the left atrial catheter over a 15-second interval. The catheter then was flushed with 2 ml of warm saline. Beginning 5 seconds before injection of the microspheres, arterial blood was withdrawn for 65 seconds at a rate of 15 ml/min with another syringe pump. During the subsequent 30-seconds, withdrawal was continued to obtain another sample used to verify the disappearance of radioactivity from arterial blood. Myocardial blood flow was calculated from the formula, QM = QA X (C M /C A ) X 100, in which Q M = myocardial perfusion in ml/min per 100 g fresh myocardium, Q A = rate of arterial withdrawal in ml/min, CA = total radioactivity in dpm recovered in the arterial withdrawal, and CM = radioactivity in dpm per g fresh myocardium.
Experimental Protocol
No heparin, sedatives, or antiarrhythmic agents were administered. The implanted catheters and leads of the flow transducers were connected to the recording instruments. After stabilization of the monitored parameters, the LAD was occluded. Twenty-nine minutes after occlusion, an initial injection of microspheres ( 85 Sr = FLOW 1) was given. Administration of nifedipine in treated dogs (n = 11) or of its vehicle in control animals (n = 10) was begun immediately after the first injection of microspheres. In treated dogs, a loading dose of nifedipine (5 jiig/kg, iv) was administered slowly over a 3minute interval followed by continuous intravenous infusion of the drug. To give continuous infusions, battery-operated pumps (Holter model 903) connected to plastic bags containing the drug (100 jtig/ml vehicle) or the vehicle (15% polyethylene glycol and 15% ethanol in water) were used. The entire infusion system was strapped to the dog's back and covered with opaque material to prevent inactivation of the light-sensitive drug. The rate of infusion of nifedipine was adjusted to maintain a slight decrease in mean aortic pressure (<5 mm Hg) compared to the value recorded immediately before infusion and ranged between 40 and 60 jug/hour per animal (mean ± SE = 53 ± 1; n = 9).
A second injection of microspheres ( 141 Ce = FLOW 2) was given 3 minutes after the onset of the infusion of the drug or its vehicle, and hemodynamic monitoring was continued for 3 hours. In four control and four treated dogs, an injection was administered at the end of this 3-hour interval instead of at the 3-minute interval ( 14I Ce = FLOW 3). Another injection of microspheres ( 51 Cr = FLOW 4) was given 24 hours after coronary occlusion and the dogs were killed with an overdose of pentobarbital. The LAD was cannulated proximal to the snare, cut distally, and perfused with heparinized blood under a pressure head of 100 mm Hg. In all instances, the artery was completely occluded. The heart then was excised and placed on ice for immediate processing. Three dogs were not subjected to coronary occlusion but were used for sequential measurements of myocardial flow at rest.
Analysis of Myocardium
All procedures were performed at 2°C. The atria, great vessels, right ventricular free wall, large epicardial vessels, and epicardial fat were removed. The right ventricular free wall was cut along its junction with the interventricular septum and separated from the heart. The trimmed left ventricle was cut along the junction between the posterior free wall and the septum and the opened ventricle laid flat on a board.
A number 12 cork borer (i.d. ~ 19 mm) was used to cut transmural, cylindrical tissue samples as close to each other as possible. Sampling was started in the area exhibiting the most severe gross myocardial infarction and then extended to the periphery of the infarction and to the rest of the myocardium. With this technique, 85 ± 4% of the total trimmed ventricular weight (mean ± SE; n = 17) was sampled. A central, transmural core of tissue for histological studies was cut out from some samples with a number 2 cork borer (i.d. ~ 5 mm) and fixed in 10% buffered formalin. The remainder of the cylindrical samples were cut perpendicular to the long axis halfway between the epicardial and endocardial surfaces to provide "epicardial" and "endocardial" samples weighing 1.40 ± 0.29 g (mean ± SD; n = 588) and 1.36 ± 0.31 g (mean ± SD; n = 588), respectively.
Each myocardial sample was blotted, weighed, and immediately transferred to 50-ml polycarbonate centrifuge tubes. Five ml/g myocardium of icecold homogenizing medium containing Tris-chloride, pH 8.0, 50 mM, and dithiothreitol, 5 mM, were added to each tube. The muscle was minced with scissors, the scissors and walls of the tube were washed with medium (5 ml/g of initial tissue), and the suspended mince was homogenized in the same tube with a Sorvall model OM-1150 homogenizer with three 20-second bursts at maximum speed. The blade of the homogenizer was rinsed, bringing the total volume of medium in the tube to 15 ml/g wet weight of tissue. Samples then were centrifuged at 14,000 g for 20 minutes in a SS-34 rotor in a Sorvall RC-5 centrifuge and the supernatant fractions removed. Radioactivity in the tubes containing the pellets and entrapped microspheres was counted at 0°C with a Germanium-Lithium Ortec detector in conjunction with a Tracor-Northern, Econ II multichannel analyzer. The absolute activities of a5 Sr, 141 Ce, and 51 Cr were determined by integrating the narrow (~ 2 keV) energy peaks at 514, 145, and 320 keV. The Germanium-Lithium detector was used because of its selectivity and very low background. Samples with low activities were counted for up to 60 minutes (total counts > 10,000) with background counts of less than 10%. Samples of supernatant fractions were counted as well, but never exhibited more than background activity, indicating that the homogenization procedure did not liberate isotope from the microspheres. The VOL. 43, No. 3, SEPTEMBER 1978 entire processing of biopsies was performed in a single test tube. Recovery of radioactive microspheres added to test tubes before mincing the muscle was 97 ± 2% (mean ± SE; n = 10). In some experiments, the pellets were resuspended in 30 ml of medium immediately after counting, transferred to a glass-glass hand homogenizer, and homogenized with 10 full strokes. Creatine kinase (CK) activity in the supernatant fractions and in the resuspended pellets was assayed with a commercial test kit (Calbiochem STAT PAK) and expressed in international units (IU) as previously described. 14 Protein was estimated with the biuret reaction with the use of bovine serum albumin as a standard. 14 The central, transmural, formalin-fixed tissue samples were embedded in paraffin, sectioned parallel to their long axis, and stained with hematoxylin and eosin. Photomicrographs (20 X 25 cm) were obtained and infarct in the epicardial and endocardial portions was measured planimetrically as previously described ( Fig. I ). 15
Analysis of Data
CK activity in the supernatant fraction expressed as IU/g of fresh myocardium was used as an index of myocardial integrity. Depletion of CK has been shown to correlate with light microscopic, 15 ' 16 electron microscopic, 17 ultrasonic, 18 electrocardiographic, 19 and biochemical 15 criteria of myocardial ischemic injury. Perfusion to epicardial and endocardial samples before pharmacological intervention (FLOW 1) was classified into five categories: (1) >65 ml/100 g per min, (2) 31-65 ml/100 g per min, (3) 21-30 ml/100 g per min, (4) 11-20 ml/100 g per min, and (5) <10 ml/100 g per min. The limit between flow categories I and II (65 ml/100 g per min) was selected to separate samples from the ischemic anterior wall from those from the rest of the ventricle with minimum overlap. In 17 hearts, only 18 of 345 samples with flows below 65 ml/100 g per min did not originate from the anterior walls. To calculate local transmural flow, endocardial and epicardial segments derived from the original fullthickness sample were recombined and the sum of flow to both segments divided by the sum of their weights.
The significance of the difference between group means was assessed by the £-test for unpaired samples. The t-test for paired samples was applied to evaluate the significance of the difference between sequential changes in coronary flow. Coefficients of correlation were calculated by standard least squares analysis.
Results

Mortality
One control dog was found dead 4 hours and another 11 hours after coronary occlusion. In the treated group, one dog died 5 hours and another 8 hours after occlusion. Compared to survivors in the same group, these dogs exhibited no unusual changes in heart rate, rhythm, or blood pressure during the initial 3 hours of observation. Autopsies did not clarify the cause of death in any of the dogs. 
Systemic Hemodynamics
Data on systemic hemodynamics are summarized in Table 1 . Both before and 29 minutes after coronary occlusion, heart rate, mean aortic pressure, cardiac output, and left arterial pressure were similar in the control and treated groups. Treatment with nifedipine induced modest and transient decreases in aortic and left atrial pressures, and significant increases in heart rate 33 minutes and 3.5 hours after coronary occlusion. Compared to results in control dogs, cardiac output was significantly increased at all times in dogs given nifedipine. Cardiac output was increased by 39%, 33 minutes after coronary occlusion, and by 22% both 3.5 hours and 24 hours after occlusion. The ratio of arterial pressure in mm Hg to cardiac output in ml/min per kg body weight, an index of total systemic vascular resistance, averaged 0.71 ± 0.04 (SE) and 0.72 ± 0.05, 3.5 and 24 hours after occlusion in the control animals, and 0.56 ± 0.03 and 0.57 ± 0.03 in the treated dogs. The differences between the two groups were highly significant (P < 0.001).
Myocardial Blood Flow
In three resting, unrestrained dogs not subjected to coronary ligation, 85 Sr, 141 Ce, and 51 Cr microspheres were injected serially at 5-minute intervals. Initial heart rate and mean aortic pressure averaged 88, 71, and 78 beats/min and 103, 86, and 82 mm Hg. During the interval encompassing these sequential infusions of microspheres, aortic pressure in each dog varied by less than 2 mm Hg, and heart rate changed by no more than 6 beats/min. In each dog, 10 contiguous transmural samples (2.46 ± 0.11 g; mean ± SE) from the anterior wall of the left ventricle were studied. Sequential flows to the 10 segments averaged 82 ± 5 (SE), 77 ± 4, and 84 ± 6 ml/100 g per min in the first dog, 68 ± 4, 65 ± 5, and 71 ± 5 ml/100 g per min in the second dog, and 72 ± 4, 73 ± 5, and 64 ± 4 ml/100 g per min in the third dog. The sequential flows in each dog were not statistically different (P > 0.05, t-test for paired samples). Although the variation of these measurements is considerable, it is comparable to that observed by others using similar methods. 13 ' 20~24 Table 2 displays the values of flow in subendocardial samples from control and treated dogs whose systemic hemodynamic data are summarized in Table 1 . The frequency of the samples was minimum in category II and exhibited relative maxima in categories I and IV, suggesting a bimodal flow distribution. In control dogs ( Table 2, upper panel) , flow values for nonischemic, category I samples did not change appreciably during the course of the study. However, they were higher than values observed in the three dogs without coronary occlusion. In categories III and IV, flows 3.5 and 24 hours after occlusion were significantly increased compared to values 29 minutes after occlusion. However, samples with markedly depressed flows (category V) failed to exhibit increases in flow with time. In treated dogs ( Table 2 , lower panel), the relative frequency of the samples in each flow category was similar to that seen in the control dogs. Nifedipine increased perfusion both in nonischemic (category I) and ischemic myocardium (categories II-IV). Compared to the values at 29 minutes, flows after onset of treatment at 33 minutes were increased by 91 ± 3%, 104 ± 11%, 76 ± 5%, and 46 ± 3% (mean ± SE) in categories I, II, III, and IV. Significant increases in flow also were noted 3.5 and 24 hours after occlusion, indicating that the effect of nifedipine was sustained. On the other hand, the drug failed to increase flow in the most severely ischemic samples (category V). Table 3 summarizes results for epicardial samples. Compared to the endocardial samples, initial flows in nonischemic samples (category I) were slightly but significantly (P < 0.001) lower. In control dogs ( Table 3 , upper panel), flows in categories II to IV were significantly increased 3.5 and 24 hours after occlusion compared to the initial flows at 29 minutes. Samples with markedly depressed flows (category V) remained severely ischemic throughout the study. In the treated group (Table   TABLE 1 Values are means ± SE. The number of dogs and number of samples contributing to mean values are indicated by the roman and arabic numbers in parentheses, respectively. § = significantly different from the value at 29 minutes in the same flow category; * = significantly different from the preceding value in the same flow category (P < 0.05, paired /-tests); f = significantly different from the value in the control group in the corresponding flow category at thj same time after occlusion (P < 0.05, Mest for unpaired samples).
3, lower panel)
, nifedipine augmented flow to nonischemic and moderately ischemic samples (categories I-IV) but failed to increase flow to the most severely ischemic samples (category V). Compared to the corresponding flows in control dogs, increases in flow were most marked 33 minutes after occlu-sion, but remained significantly (P < 0.05) elevated throughout the study. Thus, effects of nifedipine on perfusion of epicardial samples were qualitatively similar to those observed in endocardial samples.
To evaluate the effects of ischemia and nifedipine on the transmural distribution of flow, the ratios of Protocol, values expressed, statistical analyses, and abbreviations (numbers in parentheses, §, ', t) as those indicated in the footnote to Table 2. the same endocardial to epicardial flow were calculated (Table 4 ). In control dogs, the ratios for the samples with the highest flows (category I) were above unity, indicating preponderant flow to the subendocardial layer. In contrast, transmural samples with moderately depressed initial flows (categories II-IV) exhibited ratios below unity, indicative of impaired perfusion of the inner layer. In samples with very severe ischemia (category V), ratios were less depressed than in those with moderate ischemia. Compared to the initial ratios 29 minutes after occlusion, ratios at 24 hours remained unchanged in category I but increased significantly in categories II-IV. Thus, subendocardial ischemia tended to diminish with time. Treated dogs exhibited similar transmural flow distributions. Nifedipine slightly increased the endocardial-to-epicardial flow ratios 33 minutes after occlusion, but these changes were not statistically significant (P > 0.05). Thus, doses of nifedipine that produced slight tachycardia and minimal or no arterial hypotension increased perfusion to the nonischemic and ischemic myocardium but did not alter the transmural flow distribution.
Myocardial Creatine Kinase Activity
Myocardial CK activity was measured in the samples that were used for flow analyses ( Table 5 ). The supernatant fraction from samples with high flow (category I) contained more than 2000 IU/g myocardium, a value typical of intact canine myocardium. 25 In samples with depressed flow (categories II-V), CK activity in the supernatant fraction decreased in proportion to the severity of ischemia. Activity was only about 10% of normal in the most severely ischemic samples. Decreases in CK activity in the resuspended pellets paralleled those observed in the supernatant fractions. In flow categories II-V, endocardial samples exhibited significantly (P < 0.05) greater depressions in CK activity compared to epicardial samples.
Treatment with nifedipine preserved CK activity in ischemic myocardium. Endocardial samples in categories II-V and epicardial samples in categories III-V exhibited significantly (P < 0.05) elevated supernatant CK activity in treated dogs compared to controls (Table 5 ). Thus, CK activity in samples matched for flow before onset of treatment was increased in the treated group. Furthermore, CK activity in samples with similar flow histories after pharmacological intervention was elevated in the treated compared to the control group. As shown in Table 2 , endocardial flow values in category III in control dogs and in category IV in treated dogs were similar 33 min, 3.5 hours, and 24 hours after occlusion. However, CK activity in these samples with similar flow profiles was significantly elevated in the treated compared to the control group (1083 To calculate local transmural flow, endocardial and epicardial segments from the same full-thickness samples were recombined and the sum of flow to both segments divided by the sum of their weights. Transmural flow values were ordered into categories I to V (first vertical column). Average endocardial-to-epicardial flow ratios for recombined samples in each transmural flow category were calculated (horizontal rows). Note that as transmural flow values represent averages of disparate endocardial and epicardial flows, samples aggregated in any flow category in this table are not necessarily contributing to the values of corresponding flow categories in Tables 2 and 3 . Values expressed are means ± SE. f = significantly different (P < 0.05) from the value at the same time after coronary occlusion in the next higher flow category of the same group of dogs. Other abbreviations (numbers in parentheses, §) are the same as those indicated in the footnote to ± 60 vs. 631 ± 39 IU/g; P < 0.001; see Table 5 ). Preservation of CK activity in the presence of similar flow histories also was evident for endocardial and epicardial samples in categories V (Tables 2, 3 , and 5). Figure 2 illustrates the relation between myocardial CK activity and necrosis estimated histologically. Infarction quantified by the morphometric method appeared to increase linearly with decreasing CK activity. Regression equations for endocardial and epicardial samples from normal and treated dogs exhibited similar slopes and intercepts (see legend to Fig. 2 ), suggesting that the relation between CK activity and morphometric infarction was the same for epicardial and endocardial myocardium and was not altered by treatment with nifedipine.
Discussion
This study was undertaken to determine whether continuous administration of nifedipine exerts a salutory effect on the severely ischemic myocardium. Because the drug is a potent coronary dilator 1 ' 3 and reduces myocardial oxygen uptake, 9 ' 10 it may be expected to improve the balance between myocardial energy supply and demand. Nifedipine appears to act on cardiac and smooth muscle by inhibiting the inward movement of calcium into cells 2 ' 3 ' 12 (R. Kaufman, personal communication). Unlike verapamil, another agent with calcium an-tagonistic effects, nifedipine does not produce atrioventricular block, 26 a desirable property for the treatment of acute myocardial infarction. Recent clinical studies on angina pectoris 27 ' 28 and acute myocardial infarction 29 suggest that coronary vasospasm may trigger and/or aggravate myocardial ischemia. Therefore, it appears important to determine whether agents capable of relieving arterial spasm may augment perfusion of the ischemic myocardium and reduce ischemic injury.
In the present study, nifedipine decreased peripheral vascular resistance and augmented cardiac output, in agreement with previous observations. 17 " 9 By reducing arterial impedance and unloading the left ventricle, nifedipine may exert a beneficial effect on the ischemic heart. 30 Increases in cardiac performance in acute myocardial infarction have been reported for other vasodilators, 30 in particular for nitroprusside. 6 Although nifedipine reduces cardiac contractility in vitro, 2 therapeutic doses of nifedipine have not been reported to reduce cardiac performance in vivo, 1 ' " 10 in agreement with the findings of the present study. In this series of experiments, nifedipine produced greater increases in coronary flow than in aortic flow, confirming the selectivity of the drug for the coronary vascular bed. 1 ' 9 In this study, radioactively labeled microspheres were used to estimate local myocardial perfusion. 13 The use of this method for the evaluation of myo- cardial ischemia has been validated by independent flow measurements with diffusible indicators. 31 ' 32 Results indicate that after occlusion of the LAD in conscious dogs, flow to the ischemic myocardium may increase significantly within 3.5 hours. Such early increases in collateral flow cannot be attributed to the formation of new collateral channels. Furthermore, they do not appear to reflect mere changes in systemic hemodynamics. Thus, in the interval between 33 minutes and 24 hours, cardiac output rose modestly from 127 to 138 ml/kg per min, and aortic and left arterial pressure remained practically unchanged. During the same period, perfusion of ischemic myocardium with initial flows ranging between 10 and 65 ml/100 g per min increased at least 1.5-fold. Recent studies in our laboratory have demonstrated that isolated canine coronary arteries respond to hypoxia with transient relaxation and subsequent sustained contraction mediated by the release of norepinephrine from the vascular nerves. 33 Coronary vasospasm limiting collateral perfusion during the first hours of sustained myocardial ischemia perhaps could explain the flow profiles observed in this study.
Continuous infusion of nifedipine produced sustained increases in flow to nonischemic and ischemic myocardium with flows between 10 and 65 ml/100 g per min. In a concentration that produced only little or no decreases in aortic and left atrial pressure, nifedipine did not alter the distribution of flow across the ventricular wall. Furthermore, ni-fedipine-induced increases in flow to moderately ischemic myocardium (10-65 ml/100 g per min) was of the same order of magnitude as that to nonischemic myocardium (>65 ml/100 g per min), indicating that flow was not diverted from ischemic to nonischemic zones ("coronary steal"). 34 However, in samples with very severe ischemia (<10 ml/100 g per min), depression in flow remained fixed throughout the study, possibly reflecting irreversible ischemic injury 0.5-hour after occlusion. Very severe transmural ischemia (<10 ml/100 g per min) exhibited endocardial-to-epicardial flow ratios which were less depressed than those observed in the next higher flow category (20-30 ml/100 g per min). There is little information in the literature on the transmural flow distribution of the very severely ischemic anterior wall of the left ventricle. Measurement of low flows by the microsphere technique lacks precision. Nevertheless, the present findings may reflect the fact that, once reduction of endocardial flow is very severe (< 10 ml/100 g per min), it cannot decrease much more, and further decreases in local perfusion may involve predominantly the outer ventricular wall and thereby augment the endocardial-to-epicardial flow ratio.
In the present study, myocardial CK activity and deposition of microspheres were measured in the same tissue sample. Both epicardial and endocardial samples exhibited increasing depression in CK activity with increasingly severe ischemia. For any given degree of ischemia, loss in enzyme activity was more severe for endocardial than for epicardial samples, indicating the greater susceptibility of the inner myocardial layer to ischemia. Compared to the control group, CK activity in the treated dogs was increased for a given degree of ischemia prior to pharmacological intervention. In addition, CK activity was less depressed with respect to myocardial perfusion 3.5 and 24 hours after occlusion, suggesting that nifedipine exerted a favorable effect independent of changes in myocardial perfusion. Recent experiments in our laboratory have demonstrated that nifedipine inhibits calcium accumulation and ischemic injury in rabbit hearts perfused at constant low flow (ischemia.) 35 In other experiments, the drug was found to protect the myocardium of dogs undergoing prolonged hypothermic cardiopulmonary bypass. 36 These observations support the view that nifedipine exerts a direct or flowindependent protective effect on ischemic cardiac muscle. CK activity in ischemic myocardial samples correlated well with infarction determined by morphometric analysis, and treatment with nifedipine did not alter the relationship between loss in CK activity and extent of morphological injury.
In conclusion, the present study indicates that in conscious dogs with acute coronary occlusion nifedipine increases collateral perfusion of ischemic myocardium and reduces ischemic injury assessed enzymatically and histologically.
